Valuation: PolyPid Ltd.

Market Cap 74.78M 65.68M 61.08M 56.05M 105M 7.2B 107M 725M 283M 3.54B 281M 275M 12.24B P/E 2026 *
-4.6x
P/E 2027 * -3.5x
Enterprise Value 74.78M 65.68M 61.08M 56.05M 105M 7.2B 107M 725M 283M 3.54B 281M 275M 12.24B EV / Sales 2026 *
4.99x
EV / Sales 2027 * 8.71x
Free-Float
78.77%
Yield 2026 *
-
Yield 2027 * -
1 day-8.02%
1 week-27.37%
Current month-23.23%
1 month-14.66%
3 months-15.58%
6 months-18.41%
Current year-10.14%
1 week 3.65
Extreme 3.65
5.58
1 month 3.65
Extreme 3.65
5.73
Current year 3.65
Extreme 3.65
5.73
1 year 3.06
Extreme 3.06
5.73
3 years 2.3
Extreme 2.3
12
5 years 2.3
Extreme 2.3
289.2
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 01/07/2022
Director of Finance/CFO 39 -
Chief Operating Officer 48 01/01/2022
Director TitleAgeSince
Director/Board Member 75 01/06/2020
Director/Board Member 74 01/12/2018
Director/Board Member 84 01/04/2008
Date Insider Type Main position Quantity % Market Cap.
7/15/26 A Free

Chief Executive Officer

149,000 1.4621%
7/15/26 A Free

Director

9,132 0.0896%
7/15/26 A Free

Director

9,132 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
-8.02%-27.37%+5.98%-61.19% 74.78M
+0.86%+1.43%+47.17%+161.40% 1,067B
+1.59%+4.09%+56.51%+52.79% 635B
+0.95%+1.91%+36.30%+83.13% 458B
+1.60%+6.25%+37.00%+30.00% 347B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.81% 203B
-1.18%-3.70%+11.28%+67.43% 161B
Average -0.36%-1.54%+24.18%+41.01% 364.36B
Weighted average by Cap. +0.76%+1.95%+35.99%+78.14%

Financials

2026 *2027 *
Net sales 15M 13.17M 12.25M 11.24M 21.12M 1.44B 21.45M 145M 56.84M 710M 56.31M 55.1M 2.46B 8.58M 7.54M 7.01M 6.43M 12.09M 827M 12.27M 83.24M 32.52M 406M 32.22M 31.52M 1.4B
Net income -18.96M -16.65M -15.49M -14.21M -26.7M -1.83B -27.12M -184M -71.85M -898M -71.18M -69.65M -3.1B -27.7M -24.33M -22.63M -20.76M -39.01M -2.67B -39.62M -269M -105M -1.31B -104M -102M -4.53B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
24/07/26 $3.900 -8.02% 286,505
23/07/26 $4.240 +6.00% 302,140
22/07/26 $4.000 +6.95% 439,231
21/07/26 $3.740 -27.38% 2,229,568
20/07/26 $5.150 -4.10% 162,338
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.900USD
Average target price
12.00USD
Spread / Average Target
+207.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock